Gibson Capital LLC Invests $192,000 in Agilent Technologies, Inc. (NYSE:A)

Gibson Capital LLC bought a new position in shares of Agilent Technologies, Inc. (NYSE:A) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 1,290 shares of the medical research company’s stock, valued at approximately $192,000.

Other large investors have also modified their holdings of the company. Livelsberger Financial Advisory purchased a new stake in shares of Agilent Technologies during the fourth quarter worth $26,000. Crewe Advisors LLC boosted its position in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 101 shares during the last quarter. Ridgewood Investments LLC acquired a new position in shares of Agilent Technologies during the 2nd quarter valued at about $29,000. Rise Advisors LLC boosted its position in shares of Agilent Technologies by 527.8% during the 1st quarter. Rise Advisors LLC now owns 226 shares of the medical research company’s stock valued at $33,000 after acquiring an additional 190 shares during the last quarter. Finally, Riverview Trust Co acquired a new position in shares of Agilent Technologies during the 1st quarter valued at about $41,000.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on A shares. TD Cowen boosted their price target on shares of Agilent Technologies from $153.00 to $160.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Bank of America boosted their price target on shares of Agilent Technologies from $140.00 to $147.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. Citigroup upped their target price on shares of Agilent Technologies from $150.00 to $165.00 and gave the company a “buy” rating in a research report on Thursday, August 22nd. Barclays upped their target price on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “underweight” rating in a research report on Friday, August 23rd. Finally, UBS Group upped their target price on shares of Agilent Technologies from $141.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, August 22nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, Agilent Technologies presently has a consensus rating of “Moderate Buy” and an average target price of $143.64.

Insider Buying and Selling

In related news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total transaction of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares in the company, valued at approximately $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Agilent Technologies news, SVP Dominique Grau sold 9,990 shares of the stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the transaction, the senior vice president now directly owns 40,011 shares in the company, valued at $5,801,595. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the completion of the transaction, the chief executive officer now owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,953 shares of company stock worth $2,013,630.

Agilent Technologies Stock Up 0.8 %

Shares of NYSE:A opened at $143.82 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.78 and a quick ratio of 1.37. The firm has a market capitalization of $41.32 billion, a PE ratio of 29.84, a price-to-earnings-growth ratio of 6.96 and a beta of 1.05. The firm’s 50-day moving average is $140.51 and its two-hundred day moving average is $138.94. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.06. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The company had revenue of $1.58 billion for the quarter, compared to analyst estimates of $1.56 billion. During the same period in the prior year, the firm earned $1.43 earnings per share. The business’s revenue for the quarter was down 5.6% compared to the same quarter last year. Analysts predict that Agilent Technologies, Inc. will post 5.24 EPS for the current year.

Agilent Technologies Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 23rd. Investors of record on Tuesday, October 1st will be paid a dividend of $0.236 per share. The ex-dividend date of this dividend is Tuesday, October 1st. This represents a $0.94 dividend on an annualized basis and a dividend yield of 0.66%. Agilent Technologies’s payout ratio is 19.50%.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.